Jazz Pharmaceuticals plc (JAZZ): who owns it and who trades it
As of Nov 16, 2026, JAZZ insiders reported 67 open-market sales worth $87.9M and no purchases in the last 12 months, with 40% of the sale value made under pre-set 10b5-1 plans. The largest seller was Bruce C Cozadd (Director), with $45.3M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Jazz Pharmaceuticals
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns JAZZ
641 funds and institutions reported JAZZ shares worth $15.6B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 9.5%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 5.97M | 9.51% | $1.4B | +7% |
| FMR LLC (Fidelity) | 4.61M | 7.35% | $1.1B | +103% |
| Vanguard Portfolio Management LLC | 3.04M | 4.84% | $732M | +2% |
| Vanguard Capital Management LLC | 2.73M | 4.35% | $658M | +3% |
| Capital World Investors | 2.70M | 4.30% | $650M | +1% |
| Lsv Asset Management | 2.28M | 3.63% | $548M | -5% |
| Franklin Resources Inc | 2.04M | 3.25% | $492M | +4% |
| State Street Corp | 2.00M | 3.19% | $482M | +6% |
| Dimensional Fund Advisors LP | 1.71M | 2.73% | $413M | -10% |
| Fuller & Thaler Asset Management, Inc. | 1.64M | 2.61% | $395M | -2% |
| Bank of New York Mellon Corp | 1.58M | 2.52% | $380M | -6% |
| AQR Capital Management LLC | 1.52M | 2.43% | $360M | +14% |
| Geode Capital Management, LLC | 1.48M | 2.36% | $357M | +20% |
| Ameriprise Financial Inc | 1.22M | 1.94% | $293M | -24% |
| JPMorgan Chase & Co | 1.16M | 1.85% | $277M | – |
| Bank of America Corp | 1.14M | 1.81% | $274M | +12% |
| Citadel Advisors LLC | 1.01M | 1.60% | $243M | -20% |
| Swedbank AB | 968,092 | 1.54% | $233M | -2% |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 799,297 | 1.27% | $193M | -10% |
| Millennium Management LLC | 763,880 | 1.22% | $184M | -39% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, JAZZ insiders reported $0 of open-market purchases and $87.9M of sales. 40% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 6, 2026 | Bruce C Cozadd | Director | Sale | 27,714 | $234.91 | $6.5M | Form 4 |
| Nov 6, 2026 | Bruce C Cozadd | Director | Sale | 10,688 | $235.82 | $2.5M | Form 4 |
| Nov 6, 2026 | Bruce C Cozadd | Director | Sale | 24,483 | $236.84 | $5.8M | Form 4 |
| Nov 6, 2026 | Bruce C Cozadd | Director | Sale | 5,923 | $237.39 | $1.4M | Form 4 |
| Nov 4, 2026 | Patricia Carr | Vice president | Sale | 1,250 | $231.37 | $289K | Form 4 |
| Nov 4, 2026 | Patricia Carr | Vice president | Sale | 163 | $231.27 | $37.7K | Form 4 |
| Nov 3, 2026 | Renee D Gala | CEO | Sale plan | 1,000 | $225.37 | $225K | Form 4 |
| Nov 2, 2026 | Bruce C Cozadd | Director | Sale plan | 6,000 | $215.84 | $1.3M | Form 4 |
| Oct 6, 2026 | Renee D Gala | CEO | Sale plan | 2,000 | $236.40 | $473K | Form 4 |
| Oct 1, 2026 | Bruce C Cozadd | Director | Sale plan | 6,000 | $230.33 | $1.4M | Form 4 |
| Sep 10, 2026 | Neena M Patil | Vice president | Sale plan | 1,200 | $240.94 | $289K | Form 4 |
| Sep 8, 2026 | Renee D Gala | CEO | Sale plan | 2,000 | $243.03 | $486K | Form 4 |
| Sep 1, 2026 | Bruce C Cozadd | Director | Sale plan | 6,000 | $250.13 | $1.5M | Form 4 |
| Aug 27, 2026 | Robert Iannone | Vice president | Sale plan | 18,187 | $247.86 | $4.5M | Form 4 |
| Aug 27, 2026 | Robert Iannone | Vice president | Sale plan | 11,423 | $248.67 | $2.8M | Form 4 |
| Aug 27, 2026 | Robert Iannone | Vice president | Sale plan | 18,113 | $250.02 | $4.5M | Form 4 |
| Aug 27, 2026 | Robert Iannone | Vice president | Sale plan | 9,259 | $251.95 | $2.3M | Form 4 |
| Aug 27, 2026 | Robert Iannone | Vice president | Sale plan | 300 | $252.76 | $75.8K | Form 4 |
| Aug 27, 2026 | Robert Iannone | Vice president | Sale plan | 19,639 | $250.60 | $4.9M | Form 4 |
| Aug 3, 2026 | Bruce C Cozadd | Director | Sale plan | 6,000 | $252.98 | $1.5M | Form 4 |
| Jul 1, 2026 | Bruce C Cozadd | Director | Sale plan | 6,000 | $240.47 | $1.4M | Form 4 |
| Jun 15, 2026 | Mark Douglas Smith | Director | Sale plan | 1,157 | $230.55 | $267K | Form 4 |
| Jun 10, 2026 | Neena M Patil | Vice president | Sale plan | 1,200 | $231.83 | $278K | Form 4 |
| Jun 1, 2026 | Bruce C Cozadd | Director | Sale plan | 6,000 | $235.12 | $1.4M | Form 4 |
| May 28, 2026 | Neena M Patil | Vice president | Sale plan | 1,192 | $236.97 | $282K | Form 4 |
| May 28, 2026 | Samantha Pearce | Vice president | Sale | 6,907 | $235.41 | $1.6M | Form 4 |
| May 22, 2026 | Rick E Winningham | Director | Sale | 2,741 | $241.57 | $662K | Form 4 |
| May 22, 2026 | Heather Ann McSharry | Director | Sale | 2,000 | $241.00 | $482K | Form 4 |
| May 1, 2026 | Bruce C Cozadd | Director | Sale plan | 6,000 | $203.33 | $1.2M | Form 4 |
| Apr 1, 2026 | Bruce C Cozadd | Director | Sale plan | 2,292 | $190.94 | $438K | Form 4 |
| Apr 1, 2026 | Bruce C Cozadd | Director | Sale plan | 3,684 | $190.22 | $701K | Form 4 |
| Apr 1, 2026 | Bruce C Cozadd | Director | Sale plan | 24 | $191.74 | $4.6K | Form 4 |
| Mar 9, 2026 | Patricia Carr | Vice president | Sale | 1,287 | $182.94 | $235K | Form 4 |
| Mar 3, 2026 | Bruce C Cozadd | Director | Sale plan | 3,159 | $186.09 | $588K | Form 4 |
| Mar 3, 2026 | Bruce C Cozadd | Director | Sale plan | 2,608 | $186.73 | $487K | Form 4 |
| Mar 3, 2026 | Bruce C Cozadd | Director | Sale plan | 233 | $187.84 | $43.8K | Form 4 |
| Feb 27, 2026 | Norbert G Riedel | Director | Sale | 3,415 | $192.00 | $656K | Form 4 |
| Feb 27, 2026 | Patricia Carr | Vice president | Sale | 1,117 | $190.91 | $213K | Form 4 |
| Feb 26, 2026 | Patricia Carr | Vice president | Sale | 1,253 | $194.11 | $243K | Form 4 |
| Feb 26, 2026 | Neena M Patil | Vice president | Sale | 875 | $192.07 | $168K | Form 4 |
| Feb 26, 2026 | Neena M Patil | Vice president | Sale | 15,555 | $190.28 | $3M | Form 4 |
| Feb 26, 2026 | Neena M Patil | Vice president | Sale | 2,916 | $189.81 | $553K | Form 4 |
| Feb 26, 2026 | Neena M Patil | Vice president | Sale | 11,529 | $191.65 | $2.2M | Form 4 |
| Feb 26, 2026 | Neena M Patil | Vice president | Sale | 3,523 | $193.58 | $682K | Form 4 |
| Feb 26, 2026 | Neena M Patil | Vice president | Sale | 1,061 | $190.00 | $202K | Form 4 |
| Feb 26, 2026 | Neena M Patil | Vice president | Sale | 549 | $190.80 | $105K | Form 4 |
| Feb 26, 2026 | Neena M Patil | Vice president | Sale | 1,784 | $191.88 | $342K | Form 4 |
| Feb 26, 2026 | Neena M Patil | Vice president | Sale | 1,009 | $192.79 | $195K | Form 4 |
| Feb 26, 2026 | Neena M Patil | Vice president | Sale | 197 | $193.60 | $38.1K | Form 4 |
| Feb 26, 2026 | Neena M Patil | Vice president | Sale | 16,602 | $192.53 | $3.2M | Form 4 |
| Feb 26, 2026 | Mary Elizabeth Henderson | Vice president | Sale | 5,343 | $194.49 | $1M | Form 4 |
| Dec 9, 2025 | Mary Elizabeth Henderson | Vice president | Sale | 2,238 | $169.51 | $379K | Form 4 |
| Dec 5, 2025 | Patricia Carr | Vice president | Sale | 160 | $171.11 | $27.4K | Form 4 |
| Dec 5, 2025 | Patricia Carr | Vice president | Sale | 4,500 | $171.20 | $770K | Form 4 |
| Nov 26, 2025 | Bruce C Cozadd | Director | Sale | 507 | $179.79 | $91.2K | Form 4 |
| Nov 26, 2025 | Bruce C Cozadd | Director | Sale | 38,126 | $177.27 | $6.8M | Form 4 |
| Nov 26, 2025 | Bruce C Cozadd | Director | Sale | 30,487 | $178.06 | $5.4M | Form 4 |
| Nov 26, 2025 | Bruce C Cozadd | Director | Sale | 8,380 | $179.23 | $1.5M | Form 4 |
| Nov 20, 2025 | Heather Ann McSharry | Director | Sale | 3,415 | $177.78 | $607K | Form 4 |
| Nov 18, 2025 | Bruce C Cozadd | Director | Sale | 3,384 | $180.09 | $609K | Form 4 |
| Nov 18, 2025 | Bruce C Cozadd | Director | Sale | 5,517 | $181.81 | $1M | Form 4 |
| Nov 18, 2025 | Bruce C Cozadd | Director | Sale | 717 | $182.60 | $131K | Form 4 |
| Nov 18, 2025 | Bruce C Cozadd | Director | Sale | 8,382 | $180.88 | $1.5M | Form 4 |
| Nov 18, 2025 | Patricia Carr | Vice president | Sale | 69 | $181.66 | $12.5K | Form 4 |
| Nov 18, 2025 | Patricia Carr | Vice president | Sale | 5,250 | $182.07 | $956K | Form 4 |
| Nov 18, 2025 | Rick E Winningham | Director | Sale | 5,500 | $180.86 | $995K | Form 4 |
| Nov 17, 2025 | Robert Iannone | Vice president | Sale plan | 7,159 | $168.26 | $1.2M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Bruce C Cozadd | Director | – | $45.3M | Nov 6, 2026 |
| Robert Iannone | EVP, Global Head of R&D & CMO | – | $20.4M | Aug 27, 2026 |
| Neena M Patil | EVP & Chief Legal Officer | – | $11.5M | Sep 10, 2026 |
| Patricia Carr | SVP, Chief Accounting Officer | – | $2.8M | Nov 4, 2026 |
| Rick E Winningham | Director | – | $1.7M | May 22, 2026 |
| Samantha Pearce | EVP, Chief Commercial Officer | – | $1.6M | May 28, 2026 |
| Mary Elizabeth Henderson | SVP, Technical Operations | – | $1.4M | Feb 26, 2026 |
| Renee D Gala | President & CEO | – | $1.2M | Nov 3, 2026 |
| Heather Ann McSharry | Director | – | $1.1M | May 22, 2026 |
| Norbert G Riedel | Director | – | $656K | Feb 27, 2026 |
| Mark Douglas Smith | Director | – | $267K | Jun 15, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
JAZZ short interest
Moderate short interest. 9.0% of JAZZ shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went up 20%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 5.80M JAZZ shares were sold short, 9.0% of the shares outstanding, down 1.1% from the report before. At the average daily volume of 755,707 shares, buying them all back would take about 7.7 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 5.80M | 9.03% | -1% | 755,707 | 7.7 |
| Oct 15, 2026 | 5.86M | 9.03% | +7% | 854,807 | 6.9 |
| Sep 30, 2026 | 5.48M | 8.44% | +17% | 845,809 | 6.5 |
| Sep 15, 2026 | 4.68M | 7.20% | +1% | 647,877 | 7.2 |
| Aug 31, 2026 | 4.62M | 7.12% | +28% | 1.26M | 3.7 |
| Aug 14, 2026 | 3.61M | 5.57% | +8% | 949,549 | 3.8 |
| Jul 31, 2026 | 3.36M | 5.17% | -12% | 629,781 | 5.3 |
| Jul 15, 2026 | 3.80M | 6.06% | +9% | 786,595 | 4.8 |
| Jun 30, 2026 | 3.50M | 5.58% | -11% | 932,540 | 3.8 |
| Jun 15, 2026 | 3.94M | 6.28% | -8% | 930,091 | 4.2 |
| May 29, 2026 | 4.29M | 6.84% | -12% | 842,467 | 5.1 |
| May 15, 2026 | 4.85M | 7.73% | -5% | 1.03M | 4.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Jazz Pharmaceuticals company events
Jazz Pharmaceuticals filed 16 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 2, 2026.
- Nov 2, 2026ResultsReleased financial results. Filing
- Oct 26, 2026ResultsReleased financial results. Filing
- Oct 9, 2026LeadershipSamantha Pearce, Executive Vice President, Chief Commercial Officer of Jazz Pharmaceuticals plc (the “Company” ), notified the Company of her intent to retire from her role as Chief Commercial Officer upon the earlier of the selection and appointment of her successor or by June 30, 2027. Filing
- Sep 23, 2026AgreementFor the purpose of extending the maturity date and repricing the outstanding U.S. dollar term loan B-2 facility incurred on July 19, 2024, on September 23, 2026, Jazz Financing Lux S.à r.l., a private limited liability company ( société à responsabilité limitée ) incorporated and existing under the… Filing
- Sep 15, 2026AnnouncementShared information with investors. Filing
- Aug 31, 2026AgreementJazz Investments I Limited, a Bermuda exempted company limited by shares and a wholly-owned subsidiary of Jazz Pharmaceuticals plc, completed its previously announced private offering of $1.25 billion of its 1.875% exchangeable senior notes due 2032, which amount includes the exercise in full by… Filing
- Aug 25, 2026AnnouncementJazz Pharmaceuticals plc issued a press release announcing that the U.S. Food and Drug Administration approved two Ziihera® (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive (HER2+) gastroesophageal… Filing
- Aug 10, 2026AgreementJazz Pharmaceuticals, Inc., a wholly owned subsidiary of Jazz Pharmaceuticals Public Limited Company, entered into an Agreement and Plan of Merger with Knight Acquisition Corp., a Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, Actio Biosciences, Inc., a Delaware… Filing
- Aug 10, 2026AnnouncementShared information with investors. Filing
- Aug 3, 2026ResultsReleased financial results. Filing
- Jul 24, 2026VoteReported shareholder vote results. Filing
- May 29, 2026LeadershipAnne O’Riordan, a Class III director whose term expires at the Jazz Pharmaceuticals plc 2026 annual meeting of shareholders, has informed the board of directors that she will not stand for re-election. Filing
- May 5, 2026ResultsReleased financial results. Filing
- Feb 24, 2026ResultsReleased financial results. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
- Nov 17, 2025AnnouncementJazz Pharmaceuticals plc issued a press release announcing positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera ® (zanidatamab-hrii) in combination with chemotherapy, and with or without the checkpoint inhibitor tislelizumab, as a first-line treatment for HER2-positive… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Jazz Pharmaceuticals financials
Famous investors that hold JAZZ
4 of the 50 well-known investors we track reported holding JAZZ in their latest 13F filing. The largest position is Ken Griffin's, worth $248M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 1.07M | $248M | 0.1% | +7% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 483,573 | $112M | 0.2% | -14% |
| Israel Englander · Millennium Management | Q3 2026 | 164,259 | $38M | 0.0% | -78% |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 145,155 | $33.6M | 0.1% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named JAZZ in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 5, 2026 | FMR LLC | 13G/A | 8.6% |
| Nov 5, 2026 | FMR LLC | 13G/A | 8.6% |
Questions about Jazz Pharmaceuticals plc (JAZZ) stock
Who owns the most JAZZ stock?
The largest reported owner of Jazz Pharmaceuticals plc (JAZZ) is BlackRock, Inc., with 9.5% of the company. In total, 641 funds and institutions reported holding JAZZ at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are JAZZ insiders buying or selling?
In the last 12 months, JAZZ insiders reported no open-market purchases and 67 sales worth $87.9M. The latest trade was on Nov 6, 2026. See every trade.
What is the short interest in JAZZ?
As of Oct 30, 2026, 5.80M JAZZ shares were sold short, 9.0% of the shares outstanding, down 1.1% from the report before. At the average daily volume of 755,707 shares, buying them all back would take about 7.7 trading days (days to cover). See the history.
Which famous investors hold JAZZ?
4 of the 50 well-known investors we track reported JAZZ in their latest 13F filing, including Ken Griffin, Jim Simons, Israel Englander. The largest position is worth $248M. See all holders.
Executive pay
Jazz Pharmaceuticals's chief executive was paid a total of $15.5M for the year ended Dec 31, 2024, up 1% from $15.3M the year before. In the last 12 months, Jazz Pharmaceuticals's executives and directors bought no stock on the open market and sold $87.9M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.